1. Morikov, D. D., Morikova, E. G., & Dvornichenko, V. V. (2015). Pharmacoeconomic analysis of the use of hepatoprotectors in management of drug-associated liver injury due to Hodgkin’s lymphoma chemotherapy. Antibiot Chemoter, 60(7–8), 23–26.
2. Sokar, S. S., El-Sayad, M. E.-S., Ghoneim, M. E.-S., & Shebl, A. M. (2017). Combination of Sitagliptin and Silymarin ameliorates liver fibrosis induced by carbon tetrachloride in rats. Biomedicine & Pharmacotherapy, 89, 98–107.
3. Jimenez-Arellanes, M. A., Gutierrez-Rebolledo, G. A., Meckes-Fischer, M., & Leon-Díaz, R. (2016). Medical plant extracts and natural compounds with a hepatoprotective effect against damage caused by antitubercular drugs: a review. Asian Pacific Journal of Tropical Medicine, 9(12), 1141–1149.
4. Myshkin, V. A., & Enikeev, D. A. (2009). Oxymethyluracil and experimental pathology of the liver. Bashkortostan’s Medical Bulletin, 4(2), 147–151.
5. Tauki, A. N., Fedorov, V. N., Kunitsa, Z. A., Smirnov, N. A., & Kochneva, N. V. (2010). Comparative effects of different medications in experimental toxic hepatitis. Ivan Pavlov Russian Medical and Biological Bulletin, 1, 66–73.